CBG and Skin: Receptor Expression, Inflammation, and Early Research

Of the organs in the body that express cannabinoid receptors, the skin is one of the most accessible and one of the most complex. It expresses CB1, CB2, TRPV1, and PPAR-γ — the four receptor types most relevant to cannabinoid pharmacology — across several distinct tissue types and cell populations. Each receptor population has a different distribution, a different function, and a different relationship to the conditions that skin research typically examines. Before reading any specific CBG skin finding, understanding that receptor landscape is essential context.

The Skin's Receptor Landscape

The skin is a multi-layered structure whose different layers serve different functions and express cannabinoid receptors in different patterns. Mapping those patterns is the starting point for understanding what CBG's receptor profile actually engages when applied topically or when studied in isolated skin tissue.

Epidermis — Keratinocytes and Barrier Function

Keratinocytes — the primary structural cells of the epidermis — express CB1 receptors and, to a lesser extent, CB2. Keratinocyte proliferation and differentiation are regulated in part through CB1 signalling, which is why the CBG skin inflammation research — specifically the Wilkinson (2016) study showing CBG reducing keratinocyte proliferation in a psoriasis model — is focused on this cell population. TRPV1 is also expressed in keratinocytes and is involved in regulating skin barrier function and the response to irritants. PPAR-γ is expressed in keratinocytes and has anti-inflammatory effects in epidermal tissue.

Dermis — Fibroblasts, Immune Cells, and Sebaceous Glands

The dermis contains fibroblasts — the structural cells responsible for collagen synthesis and wound healing — which express CB1 and CB2. Dermal immune cells, including mast cells and dendritic cells, express CB2 predominantly. Mast cell activity — which drives much of the immediate hypersensitivity response in skin conditions like eczema — is modulated through CB2 signalling. Sebaceous glands, which produce sebum, express CB2 and TRPV1 extensively. CBD's anti-sebum research — the most directly examined cannabinoid-sebaceous gland interaction in the literature — operates through CB2 and TRPV1 in sebocytes, the sebaceous gland cells.

Hair Follicles

Hair follicles express CB1 throughout the follicular epithelium and CB2 in the dermal papilla — the structure that controls follicular growth cycling. Endocannabinoid signalling has been shown to inhibit hair shaft elongation and induce the regression phase of the hair cycle in organ culture models. This research thread is largely independent of the inflammation and antimicrobial research that is more directly relevant to topical CBG applications, but the receptor expression is part of the complete skin ECS picture.

What CBG's Receptor Profile Means in Skin

CBG engages several of the receptor types expressed in skin tissue through its documented mechanisms. Partial CB1 and CB2 agonism, TRPV1 interaction, and PPAR-γ activation are all relevant to the skin receptor landscape described above. Understanding which mechanisms are active at which tissue locations helps frame what CBG skin research is actually measuring.

The keratinocyte proliferation finding — CBG reducing abnormal proliferation in a psoriasis cell culture model — operates through CB1 agonism in epidermal tissue. This is the most directly published CBG skin finding, and it is covered in detail in the CBG and Skin Inflammation article. The key point here is that it represents one specific interaction at one specific receptor population in one specific tissue layer, not a general "skin benefit."

CBG's PPAR-γ activation is relevant to both epidermal and dermal tissue, where PPAR-γ has documented anti-inflammatory effects across multiple cell types. CBG's CB2 agonism is relevant to dermal immune cells — the mast cells and dendritic cells whose activation drives inflammatory skin responses. CBG's TRPV1 activity is relevant to both keratinocyte barrier function and sebaceous gland regulation.

What this adds up to is not a simple picture of "CBG is good for skin." It is a mechanistically grounded set of research hypotheses: that CBG, applied to specific skin tissue types, engages receptors whose activation has been shown in preclinical models to modulate the processes relevant to several skin conditions. Each of those hypotheses requires its own research to evaluate properly.

CBG's Antioxidant Properties in Skin Context

Beyond receptor-mediated mechanisms, CBG has documented antioxidant properties — the ability to reduce oxidative stress through free radical scavenging and through upregulation of endogenous antioxidant pathways. Oxidative stress is a contributor to skin ageing, photodamage, and several inflammatory skin conditions. In the skin, where UV exposure creates significant oxidative load, antioxidant activity is directly relevant.

CBG's antioxidant activity has been documented in cell culture and is considered one of its more robust preclinical properties — it holds across multiple model systems. Whether this translates to meaningful antioxidant effects when CBG is applied topically depends on the penetration question: does CBG reach the relevant cell populations in sufficient concentration to produce measurable antioxidant effects? The answer to that question has not been tested in human skin with the rigour needed to make confident claims.